Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among...
Allarity Therapeutics reports positive Phase 2 trial results for stenoparib in ovarian cancer and expands laboratory services.Quiver AI SummaryAllarity Therapeutics has reported significant progress in...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR). Such...
Allarity Therapeutics (NASDAQ: ALLR), a clinical-stage pharmaceutical company, recently announced preliminary results from its Phase 2 clinical trial assessing the
New strategy aligns with ongoing shift in oncology standard-of-caretowards combination therapies Combination therapy focus expected to improve the...
Board Appoints James G. Cullem, J.D., to Interim Chief Executive Officer,Joan Y. Brown, CPA, to Interim Chief Financial Officer Press release ...
Cambridge, MA U.S.A. (June 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel...